NasdaqGM:CDNABiotechs
CareDx Lawsuit Resolution Refocuses Attention On Valuation And Growth Prospects
CareDx (NasdaqGM:CDNA) disclosed that a long standing qui tam lawsuit has been dismissed.
The company had previously announced that the Department of Justice closed a related investigation without findings of wrongdoing.
Together, these outcomes remove a material legal overhang tied to historical compliance questions.
CareDx focuses on transplant diagnostics and related services, an area where regulatory oversight and reimbursement policies are central to the business model. For investors...